Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
A premature termination codon (PTC) Arg-TGA in mRNA occurs when a point mutation converts a codon for arginine (such as CGA) to the stop codon TGA within a gene's coding sequence. This results in the early termination of translation, leading to truncated, usually nonfunctional, and sometimes toxic protein products. The truncated mRNA may also be rapidly degraded by the nonsense-mediated decay pathway. PTCs are significant contributors to severe genetic diseases, including cystic fibrosis, Duchenne muscular dystrophy, and many others. Therapeutically, small molecules and engineered tRNAs are being explored to enable readthrough of PTCs, restoring some full-length protein production.
Promoting translational readthrough of premature stop codons (e.g., by Ataluren or aminoglycosides)
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Premature termination codon caused by Arg-to-TGA mutation in mRNA.